Barbara Eichhorst
Department I of Internal Medicine, University Hospital Cologne · Universitätsklinikum Köln · German CLL Study Group
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Barbara Eichhorst as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:04 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT05197192 · A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLLGerman CLL Study Group · recruiting · Chronic Lymphocytic Leukemia · principal investigator
- Ph2NCT04883749 · Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLLGerman CLL Study Group · completed · Chronic Lymphoid Leukemia · principal investigator
- Ph2NCT04271956 · Efficacy and Safety of Zanubrutinib Plus Tislelizumab Treatment With or Without Sonrotoclax for Patients With Richter TransformationGerman CLL Study Group · recruiting · Richter Transformation · principal investigator
- Ph3NCT03836261 · Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLLAcerta Pharma BV · active not recruiting · Chronic Lymphocytic Leukemia · principal investigator
- Ph3NCT02950051 · Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 MutationGerman CLL Study Group · completed · Chronic Lymphocytic Leukemia · principal investigator
- Ph3NCT01556776 · A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line TherapyGerman CLL Study Group · completed · Chronic Lymphocytic Leukemia · principal investigator
- Ph3NCT00769522 · FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic LeukemiaGerman CLL Study Group · completed · Chronic Lymphocytic Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:04 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:04 UTC. The ranking covers the 200 most relevant of 80 PubMed records, and a shared surname and initials can bring in a namesake. All 80 on PubMed
- 1,532 citationsRCR 34.5
- 1,228 citationsRCR 34.9
- Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.N Engl J Med · 2018789 citationsRCR 26.9
- Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.Lancet Oncol · 2016666 citationsRCR 19.6
- 569 citationsRCR 18.4
- 507 citationsRCR 16.3
- TP53 mutation and survival in chronic lymphocytic leukemia.J Clin Oncol · 2010487 citationsRCR 10.0
- Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.N Engl J Med · 2023454 citationsRCR 43.2
- 452 citationsRCR 10.6
- 376 citationsRCR 9.6